Meanwhile, combining Tim-3 and PD-1 blocking antibodies with DC-CIK cells in vitro before administration to tumor patients can mitigate the impact of ICI on normal cells and the body's immune system and further reduce immune-related side effects during treatment. The gene discussed is HAVCR2; the disease is neoplasm.